About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Prostate Cancer Clinical Trials in Tennessee | 383 Studies

Clinical Trials Prostate CancerTennessee

Prostate Cancer Clinical Trials in Tennessee

Find 383 clinical trials for prostate cancer near Tennessee. Connect with research centers in your area.

All Prostate Cancer trials nationwide All trials in Tennessee

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 221-240 of 383 trials

CompletedPhase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate CancerThe purpose of this study is to test the safety of cabazitaxel, mitoxantrone, and prednisone (CAMP) in combination at different dose levels and to determine the highest dose that…NCT01594918·Scottsdale, Arizona and 2 others CompletedA Study of Degarelix in Patients With Prostate CancerThe purpose of this study was to see if giving Degarelix every month for 7 months then stop treatment for 7 months (intermittent therapy) would show a reduction of negative…NCT00928434·Alexander City, Alabama and 58 others

Prostate Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedDocetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer PatientsThe primary objective of this study is to compare the duration of survival between patients receiving docetaxel in combination with the GVAX® vaccine for prostate cancer versus…NCT00133224·Anchorage, Alaska and 114 others

CompletedA Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone AcetateA 2-part, Phase 1-2, open-label, parallel group, randomized study in patients with Castration-Resistant Prostate Cancer (CRPC) who are no longer responding to treatment with…NCT01685268·Los Angeles, California and 31 others

CompletedEfficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate CancerThe purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.NCT02200614·Homewood, Alabama and 403 others

CompletedStudy Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate CancerThis is a multi-center, open-label, Phase 1/2 study of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel and prednisone for the first-line treatment of metastatic…NCT00137436·Harvey, Illinois and 23 others

RecruitingA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsThis is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors.NCT06172478·Duarte, California and 90 others

RecruitingStudy of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy…NCT05519449·Birmingham, Alabama and 35 others

TerminatedA Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate CancerThis is a global, multi-center, open-label, randomized phase 1b/2, active-controlled safety and efficacy study of oral administration of tazemetostat in combination with…NCT04179864·San Diego, California and 23 others

Active not recruitingPhase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed…NCT06691984·Birmingham, Alabama and 163 others

RecruitingStudy of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate CancerAssessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further…NCT06800313·Colorado Springs, Colorado and 17 others

CompletedA Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYXThis is a multi-center, prospective, observational study of patients being treated with ORGOVYX.NCT05467176·Homewood, Alabama and 95 others

RecruitingStandard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerThis phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants…NCT03678025·Gilbert, Arizona and 337 others

Active not recruitingA Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPCThe purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall…NCT02489318·Homewood, Alabama and 219 others

Active not recruitingTTX-080 HLA-G Antagonist in Subjects With Advanced CancersTTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy…NCT04485013·Tucson, Arizona and 40 others

Active not recruitingA Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate CancerThe purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib combination therapies…NCT03431350·Tucson, Arizona and 49 others

TerminatedStudy of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) PathwayThis is a multicenter clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers.NCT06287463·Los Angeles, California and 8 others

Active not recruitingA Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsThe purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.NCT05787587·Phoenix, Arizona and 26 others

RecruitingTesting Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the BodyThis phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that…NCT06470243·Fayetteville, Arkansas and 173 others

TerminatedPLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with…NCT04556617·Chicago, Illinois and 7 others

PreviousPage 12 of 20Next

Other Conditions in Tennessee

Breast Cancer Lung Cancer Colorectal Cancer Melanoma Leukemia Lymphoma